Not many healthcare product executives have resumes that can boast of having run both drug and device businesses the way Ron Mstricaria did at Eli Lilly. Not content with his success at Lilly, Matricaria took early retirement to embark on the challenge of directing St. Jude Medical's transition from a successful single-product firm to a major, multi-platform device company. At both companies, Matricaria endured tough times and critics questioning his strategies, but was ultimately vindicated through the success of each company. Matricaria is the recipient of this year's Phoenix Lifetime Achievement award and spoke with IN VIVO about his career and the current state of the medical device industry.
by Stephen Levin
The current excitement surrounding the early success of drug-eluting stents represents the latest episode in the ongoing debate about whether...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.